Deepak L. Bhatt | |
---|---|
Citizenship | United States |
Alma mater | Massachusetts Institute of Technology, Cornell University, Harvard University, University of Oxford |
Known for | Cardiovascular medicine, interventional cardiology |
Scientific career | |
Fields | Clinical investigator, educator, author, cardiology |
Institutions | Cleveland Clinic, VA Medical Center, Brigham and Women's Hospital, Harvard Medical School, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai |
Website | https://deepakbhattmd.com/ |
Deepak L. Bhatt is a US interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure. As of 2024, he is the director of Mount Sinai Fuster Heart Hospital in New York City and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System. [1] [2] Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School. [3] [4] He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association presented him with its Distinguished Scientist award. [5] As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194, and an i10-index of 1,249.
Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. [6] He received his Executive MBA from the University of Oxford in 2024. [7]
He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic [8] where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. [9]
Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women’s Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. [8] In 2012, he was appointed a professor of medicine at Harvard Medical School. [10]
As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. [11] He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. [7] He serves on the Board of Directors of the American Heart Association New York City chapter. [12]
Bhatt focuses on several areas of cardiology, including interventional cardiology, heart attacks, stroke, prevention, and heart failure, as well as related areas such as high cholesterol, diabetes, and obesity. [13] AD Scientific Index ranks him as one of the top 3% of scientists worldwide in his field. [14]
Recent trials as of 2024 include:
Name, sponsor, role | Description |
---|---|
SOLOIST, Sanofi Lexicon, Chair [15] | Randomized controlled clinical trial (RCT) of sotagliflozin versus placebo in patients with diabetes and acute decompensated heart failure. |
SCORED, Sanofi Lexicon, Chair [16] | RCT of sotagliflozin versus placebo in patients with diabetes and at high cardiovascular risk. |
REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial), Amarin, Chair and PI. [17] | To determine definitively whether icosapent ethyl does or does not reduce cardiovascular risk in patients receiving intensive statin therapy. |
CHAMPION PHOENIX, Chiesi, Co-Chair and Co-PI [18] | Industry-sponsored Phase 3 trial of cangrelor versus placebo in 11,000 patients undergoing percutaneous coronary intervention. |
THEMIS, AstraZeneca, Co-Chair and Co-PI [19] | This is an international, multicenter, randomized trial of patients with diabetes and stable coronary artery disease randomized to the oral antiplatelet ticagrelor or to placebo on top of standard of care including aspirin. |
Brigham and Women’s Hospital chose Bhatt in 2014 as the Eugene Braunwald Scholar and in 2016 presented him with the Research Mentor Award, and in 2017 he was awarded the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology. [6] He was given the American College of Cardiology’s Distinguished Mentor Award in 2018, [20] and in 2019, the American Heart Association’s Distinguished Scientist Award. [5] [21] He received NLA’s Honorary Lifetime Membership Award in 2021, and the Society for Cardiovascular Angiography and Interventions’ Master Designation in 2022. [2] Also in 2022, Research.com recognized him with its Best Scientists award. [13]
Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease [22] and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. [23] He is one of the co-editors of Braunwald’s Heart Disease. [24] Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor. [25]
Bhatt was Senior Associate Editor for News and Clinical Trials for ACC.org, member of the Healio | Cardiology Today Editorial Board, [26] and Editor-in-Chief of the Journal of Invasive Cardiology, which also lists him as: [27]
As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194 and an i10-index of 1,249. [31]
Bhatt has authored or co-authored over 2,000 publications [32] and has been listed by the Web of Science Group as a highly cited researcher from 2014 to 2023. [33] [34] [35]
Bhatt's most cited, peer-reviewed articles include:
Deepak L. Bhatt | |
---|---|
Citizenship | United States |
Alma mater | Massachusetts Institute of Technology, Cornell University, Harvard University, University of Oxford |
Known for | Cardiovascular medicine, interventional cardiology |
Scientific career | |
Fields | Clinical investigator, educator, author, cardiology |
Institutions | Cleveland Clinic, VA Medical Center, Brigham and Women's Hospital, Harvard Medical School, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai |
Website | https://deepakbhattmd.com/ |
Deepak L. Bhatt is a US interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure. As of 2024, he is the director of Mount Sinai Fuster Heart Hospital in New York City and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System. [1] [2] Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School. [3] [4] He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association presented him with its Distinguished Scientist award. [5] As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194, and an i10-index of 1,249.
Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. [6] He received his Executive MBA from the University of Oxford in 2024. [7]
He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic [8] where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. [9]
Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women’s Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. [8] In 2012, he was appointed a professor of medicine at Harvard Medical School. [10]
As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. [11] He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. [7] He serves on the Board of Directors of the American Heart Association New York City chapter. [12]
Bhatt focuses on several areas of cardiology, including interventional cardiology, heart attacks, stroke, prevention, and heart failure, as well as related areas such as high cholesterol, diabetes, and obesity. [13] AD Scientific Index ranks him as one of the top 3% of scientists worldwide in his field. [14]
Recent trials as of 2024 include:
Name, sponsor, role | Description |
---|---|
SOLOIST, Sanofi Lexicon, Chair [15] | Randomized controlled clinical trial (RCT) of sotagliflozin versus placebo in patients with diabetes and acute decompensated heart failure. |
SCORED, Sanofi Lexicon, Chair [16] | RCT of sotagliflozin versus placebo in patients with diabetes and at high cardiovascular risk. |
REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial), Amarin, Chair and PI. [17] | To determine definitively whether icosapent ethyl does or does not reduce cardiovascular risk in patients receiving intensive statin therapy. |
CHAMPION PHOENIX, Chiesi, Co-Chair and Co-PI [18] | Industry-sponsored Phase 3 trial of cangrelor versus placebo in 11,000 patients undergoing percutaneous coronary intervention. |
THEMIS, AstraZeneca, Co-Chair and Co-PI [19] | This is an international, multicenter, randomized trial of patients with diabetes and stable coronary artery disease randomized to the oral antiplatelet ticagrelor or to placebo on top of standard of care including aspirin. |
Brigham and Women’s Hospital chose Bhatt in 2014 as the Eugene Braunwald Scholar and in 2016 presented him with the Research Mentor Award, and in 2017 he was awarded the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology. [6] He was given the American College of Cardiology’s Distinguished Mentor Award in 2018, [20] and in 2019, the American Heart Association’s Distinguished Scientist Award. [5] [21] He received NLA’s Honorary Lifetime Membership Award in 2021, and the Society for Cardiovascular Angiography and Interventions’ Master Designation in 2022. [2] Also in 2022, Research.com recognized him with its Best Scientists award. [13]
Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease [22] and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. [23] He is one of the co-editors of Braunwald’s Heart Disease. [24] Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor. [25]
Bhatt was Senior Associate Editor for News and Clinical Trials for ACC.org, member of the Healio | Cardiology Today Editorial Board, [26] and Editor-in-Chief of the Journal of Invasive Cardiology, which also lists him as: [27]
As of 2024, Google Scholar reports that he has been cited 279,202 times, has an h-index of 194 and an i10-index of 1,249. [31]
Bhatt has authored or co-authored over 2,000 publications [32] and has been listed by the Web of Science Group as a highly cited researcher from 2014 to 2023. [33] [34] [35]
Bhatt's most cited, peer-reviewed articles include: